Literature DB >> 23657379

FDA moves on breakthrough therapies.

Jeffrey L Fox.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23657379     DOI： 10.1038/nbt0513-374a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Rare-disease drugs boosted by new Prescription Drug User Fee Act.

Authors:  Jeffrey L Fox
Journal:  Nat Biotechnol       Date:  2012-08       Impact factor: 54.908
  1 in total
  2 in total

1.  Genentech's glyco-engineered antibody to succeed Rituxan.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

Review 2.  Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.

Authors:  Christopher P Leamon; Chandra D Lovejoy; Binh Nguyen
Journal:  Pharmgenomics Pers Med       Date:  2013-09-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.